CureVac Delisted as BioNTech Acquisition Finalizes

CureVac NL0015436031

The independent stock market journey of Tübingen-based mRNA pioneer CureVac has reached its conclusion. Following the completion of a full acquisition by its rival BioNTech, trading in CureVac shares has been officially terminated. This move erases a former market hopeful from the listings, though its foundational technology will continue under the Mainz-based company's umbrella.

The situation has changed entirely for former CureVac investors. The takeover was executed as a share exchange offer. Participating shareholders received BioNTech American Depositary Shares (ADSs) in return for their holdings. Consequently, the value of their investment is now wholly dependent on the performance of the enlarged entity. Through this deal, BioNTech gains control of CureVac's proprietary technology platform and clinical pipeline, aiming to accelerate development in mRNA-based cancer treatments and vaccines for infectious diseases.

The restructuring is now complete, with BioNTech becoming the sole owner of CureVac's operational business. This action ends its listing on the Nasdaq and other trading venues. In the final active trading days in early January, the share price hovered around the $4.66 mark, reflecting the terms of the agreed all-stock transaction.

Market Focus Turns to BioNTech

The delisting shifts the financial world's attention completely to BioNTech. Market participants and analysts will now closely monitor the efficiency of the integration process.

Key factors to watch in the coming months include:

• Financial Reporting: The upcoming quarterly results are expected to provide the first insight into the consolidated balance sheets and the costs associated with the integration.
• Pipeline Prioritization: Investors await updates on which development programs from CureVac's portfolio—particularly in oncology—will be prioritized within the BioNTech group.
• Synergy Realization: Demonstrating gains in operational efficiency will be viewed as a crucial indicator of the transaction's long-term success.

While the CureVac name disappears from the tickers, its technology remains a significant component within the biotech sector. The ultimate success of this acquisition will be measured by how swiftly BioNTech can convert these new assets into market-ready products.

@ boerse-global.de | NL0015436031 CUREVAC